Search

BioNTech SE ADR

Geschlossen

BrancheGesundheitswesen

114.01 1.41

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

112.83

Max

116.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

-294M

-834M

Verkäufe

-14M

106M

EPS

-3.03

Gewinnspanne

-790.142

Angestellte

7,807

EBITDA

-135M

-585M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+13.06% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-318M

23B

Vorheriger Eröffnungskurs

112.6

Vorheriger Schlusskurs

114.01

Nachrichtenstimmung

By Acuity

50%

50%

150 / 340 Ranking in Healthcare

BioNTech SE ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 23:26 UTC

Biontech SE shares are lower in after-market trading with no specific news identified. Broader market volatility is influenced by geopolitical developments and U.S. sanctions on Iran.

21. Aug. 2026, 20:01 UTC

Event
News
Correlated Moves

BioNTech SE shares are higher as the company prepares to present new lung cancer treatment data at the IASLC conference in 2026.

20. Aug. 2026, 23:16 UTC

Event
Correlated Moves

BioNTech SE shares are lower in after-market trading as it announces new clinical data for lung cancer treatment at the IASLC conference in 2026.

19. Aug. 2026, 23:41 UTC

Correlated Moves
Social Media

BioNTech SE is trading lower in after-market hours amid a decline in the Biotechnology sub-sector and concerns over neoantigen vaccines and capital strategies.

18. Aug. 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, amid cautious sentiment linked to fluctuations in sovereign bond yields.

17. Aug. 2026, 19:56 UTC

BioNTech SE shares are lower today, reflecting broader market trends amid rising crude oil prices and inflationary pressures. The stock peaked earlier in the session.

14. Aug. 2026, 19:26 UTC

BioNTech SE shares are higher today, continuing an upward trend since Thursday. This movement occurs despite concerns over declining U.S. retail sales data.

13. Aug. 2026, 19:21 UTC

News

BioNTech SE shares are lower as analysts adjust price targets following a significant second-quarter revenue decline and a net loss of €820.8 million.

12. Aug. 2026, 19:26 UTC

Correlated Moves

BioNTech SE's shares are higher today, supported by a significant rise in Moderna Inc. amid optimistic market sentiment following recent inflation data.

11. Aug. 2026, 20:06 UTC

BioNTech SE shares are near unchanged amid a flat market performance. The stock remains above its 20-day moving average and near the upper end of its one-month range.

10. Aug. 2026, 21:01 UTC

BioNTech SE shares are higher in after-market trading, showing stability despite broader market conditions and weaker-than-expected job growth data.

7. Aug. 2026, 19:56 UTC

News
Correlated Moves

BioNTech SE is trading higher, likely influenced by Moderna's significant gains. The stock remains above its 20-day moving average despite recent revenue declines.

6. Aug. 2026, 19:51 UTC

News
Correlated Moves

BioNTech SE shares are lower amid negative sentiment in the Biotechnology sector, following a revenue decline and CEO transition announcement.

5. Aug. 2026, 19:32 UTC

News

BioNTech SE shares are higher today after Citigroup maintained its Buy rating, lowering its price target to $125 while Evercore ISI kept its Outperform rating at $130.

4. Aug. 2026, 20:03 UTC

News
Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3. Aug. 2026, 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31. Juli 2026, 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30. Juli 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29. Juli 2026, 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28. Juli 2026, 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27. Juli 2026, 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24. Juli 2026, 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22. Juli 2026, 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21. Juli 2026, 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20. Juli 2026, 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Peer-Vergleich

Kursveränderung

BioNTech SE ADR Prognose

Kursziel

By TipRanks

13.06% Vorteil

12-Monats-Prognose

Durchschnitt 127.55 USD  13.06%

Hoch 142 USD

Tief 96 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioNTech SE ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

10

Buy

2

Halten

0

Sell

Stimmung

By Acuity

150 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat